Gsk Plc ADR (GSK)
$39.39
0.00 (0.00%)
GSK Stock Quote Delayed 30 Minutes
6 Pharmaceutical Stocks to Sell Now
For the current week, the overall ratings of six Pharmaceutical stocks are worse, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
212.12B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
6,202
Day's Range
-
52-Week Range
$33.67 - $45.92
Dividend & Yield
$1.44 (3.67%)
GSK Stock Predictions, Articles, and Gsk Plc ADR News
Who Has the Best Pharma Pipeline?
A look through Big Pharma's drug pipelines shows a lot of promise across several companies, but one firm stands out as having big-time revenue growth potential.
The 10 Best Buffett Dividend Stocks
Despite paring back on several dividend stocks last quarter, Berkshire hasn't given up on income altogether. Here are its top dividend payers.
Banking on Buyouts in Biotech: Is It Smart?
Unless you really understand medicine, it's a very risky game. The chances of a little company scoring big and getting bought out are usually slim.
Israel: Beyond the Risk, Opportunities Beckon
When you think of Israel, you probably think of conflict. But it has a strong economy and growing companies if you're willing to be a bit daring.
How to Pick the Best High-Yield Stocks in Big Pharma
Big Pharma is a great place to find yield, and health care is a sure-fire long-term bet. But rather than shake a stick at this sector, go ahead ... be picky.
HCA Hospitals Questioned About ‘Unnecessary’ Heart Surgeries
The nation's largest for-profit hospital chain is reportedly under scrutiny for cardiology services at about 10 of its 163 hospitals.
Pharma’s Q2 Earnings Lesson: The Big Picture Looks Good
The promising signs coming out of pharma this quarter doesn't mean you can just pick a stock out of a hat -- but it does mean a few are worth picking.
It’s Time to Buy the European ETF Rally
"Europe" might be the dirtiest word in investing right now, but European stocks and ETFs are trying to make amends.
10 Dividend Stocks the Market Left Behind
While investors have been flocking toward dividend stocks in a mad dash to safety, these 10 high-yielding picks have been mostly ignored.
10 Buffett Dividend Stocks Paying 3% or More
For lovers of Warren Buffett and dividends, this is the perfect storm -- a list of some of Buffett's portfolio picks that boast high yields.
9 Biotech Buyout Players to Watch
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.
HGSI Holdout Proves Profitable — for Bagels
Joint pharmaceutical developers Human Genome and GlaxoSmithKline agreed to a sweetened $14.25/share offer for HGSI, cheering Rockville-area diners.
GlaxoSmithKline to Pay $3.6B for Human Genome Sciences
GlaxoSmithKline will pay $14.25 a share, a total of $3.6 billion, to acquire its long-term research partner Human Genome Sciences.
Merck Could Have a Home Run in Sight
Merck’s new drug odanacatib can be thanked for the stock's recent rally, but there are two questions that need to be answered.
Medidata Solutions a Strong Buy in Cloud Computing
Medidata Solutions is a fast-growing cloud services provider to the health care industry that is poised for even better growth and is a buying opportunity
Glaxo to Pay $3B in Fines for Improper Drug Marketing
GlaxoSmithKline will pay $3 billion in fines relating to its promotion of the antidepressant drugs, Paxil, Wellbutrin and Avandia, and the asthma drug Advair.
Manufacturing Woes Stop the Mo: Monday’s IP Market Recap
Markets reacted to a disappointing manufacturing report, starting out in negative territory before coming back for slight gains in the S&P and Nasdaq.
3 Wall Street Deals That Fizzled in Q2
Three companies targeted for buyouts still haven't (or declined to) pull the trigger in Q2, leaving shareholders wondering whether management did right by them.
5 of Pharma’s Most Disastrous Drug Approvals
These five exciting drug approvals now serve as warning stories about the potential pitfalls for investors trying to time a pharma stock buy.
